DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.

MLA

Kagoya, Yuki, et al. “DOT1L Inhibition Attenuates Graft-versus-Host Disease by Allogeneic T Cells in Adoptive Immunotherapy Models.” Nature Communications, vol. 9, no. 1, May 2018, p. 1915. EBSCOhost, https://doi.org/10.1038/s41467-018-04262-0.

APA

Kagoya, Y., Nakatsugawa, M., Saso, K., Guo, T., Anczurowski, M., Wang, C.-H., Butler, M. O., Arrowsmith, C. H., & Hirano, N. (2018). DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. Nature Communications, 9(1), 1915. https://doi.org/10.1038/s41467-018-04262-0

Chicago

Kagoya, Yuki, Munehide Nakatsugawa, Kayoko Saso, Tingxi Guo, Mark Anczurowski, Chung-Hsi Wang, Marcus O Butler, Cheryl H Arrowsmith, and Naoto Hirano. 2018. “DOT1L Inhibition Attenuates Graft-versus-Host Disease by Allogeneic T Cells in Adoptive Immunotherapy Models.” Nature Communications 9 (1): 1915. doi:10.1038/s41467-018-04262-0.